AstraZeneca EPS - Earnings per Share 2006-2018 | AZN

AstraZeneca annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • AstraZeneca EPS for the quarter ending December 31, 2018 was $0.41, a 19.88% decline year-over-year.
  • AstraZeneca EPS for the twelve months ending December 31, 2018 was $0.85, a 28.27% decline year-over-year.
  • AstraZeneca 2018 annual EPS was $0.85, a 28.27% decline from 2017.
  • AstraZeneca 2017 annual EPS was $1.19, a 14.13% decline from 2016.
  • AstraZeneca 2016 annual EPS was $1.38, a 23.77% increase from 2015.
AstraZeneca Annual EPS
2018 $0.85
2017 $1.19
2016 $1.38
2015 $1.12
2014 $0.49
2013 $1.02
2012 $2.47
2011 $3.63
2010 $2.79
2009 $2.60
2008 $2.10
2007 $1.87
2006 $1.93
2005 $1.46
AstraZeneca Quarterly EPS
Q4 2018 $0.41
Q3 2018 $0.17
Q2 2018 $0.14
Q1 2018 $0.13
Q4 2017 $0.51
Q3 2017 $0.27
Q2 2017 $0.19
Q1 2017 $0.21
Q4 2016 $0.73
Q3 2016 $0.40
Q2 2016 $0.00
Q1 2016 $0.26
Q4 2015 $0.32
Q3 2015 $0.30
Q2 2015 $0.28
Q1 2015 $0.22
Q4 2014 $-0.13
Q3 2014 $0.10
Q2 2014 $0.32
Q1 2014 $0.20
Q4 2013 $-0.21
Q3 2013 $0.50
Q2 2013 $0.33
Q1 2013 $0.41
Q4 2012 $0.61
Q3 2012 $0.60
Q2 2012 $0.63
Q1 2012 $0.64
Q4 2011 $0.58
Q3 2011 $1.27
Q2 2011 $0.77
Q1 2011 $1.04
Q4 2010 $0.57
Q3 2010 $0.54
Q2 2010 $0.73
Q1 2010 $0.96
Q4 2009 $0.54
Q3 2009 $0.73
Q2 2009 $0.59
Q1 2009 $0.74
Q4 2008 $0.43
Q3 2008 $0.60
Q2 2008 $0.56
Q1 2008 $0.52
Q4 2007 $0.43
Q3 2007 $0.46
Q2 2007 $0.48
Q1 2007 $0.51
Q4 2006 $0.47
Q3 2006 $0.51
Q2 2006 $0.51
Q1 2006 $0.45
Q4 2005 $0.39
Q3 2005 $0.38
Q2 2005 $0.38
Q1 2005 $0.32
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.150B $22.090B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.784B 16.77
Pfizer (PFE) United States $232.043B 12.99
Merck (MRK) United States $198.062B 16.93
Novartis AG (NVS) Switzerland $174.174B 14.81
Eli Lilly (LLY) United States $119.606B 20.77
Novo Nordisk (NVO) Denmark $117.534B 19.01
AbbVie (ABBV) United States $115.278B 9.88
Sanofi (SNY) France $103.709B 12.80
GlaxoSmithKline (GSK) United Kingdom $98.430B 12.93
Bristol-Myers Squibb (BMY) United States $73.920B 11.37